Guest session of *Introduction to Applied Mathematics and Informatics In Drug Discovery (AMIDD)*

December 6th, 2019, 12:15-13:00

Seminarraum 5.002, Department of Mathematics and Informatics, University of Basel, Spiegelgasse 1, 4051 Basel

Interim look into pivotal clinical trials - why it matters and how to do it

Speaker: Dr. Kaspar Rufibach

Kaspar Rufibach is a member of Roche's Methods, Collaboration, and Outreach group and located in Basel. He does methodological research, provides consulting to Roche statisticians and broader project teams, gives biostatistics trainings for statisticians and non-statisticians in- and externally, mentors students, and interacts with external partners in industry and the academic community in various working groups. He has co-founded and co-leads the Oncology estimand EFSPI Special Interest Group that currently has more than 30 members from 19 companies and several Health Authorities, and works on various topics around estimands in oncology. Research interests are methods to optimize study designs, advanced survival analysis, probability of success, estimands, estimation of treatment effects in subgroups, and general nonparametric statistics. Before joining Roche, Kaspar received training and worked as a statistician at the Universities of Bern, Stanford, and Zurich.

Find more on http://www.kasparrufibach.ch/

Guest session of *Introduction to Applied Mathematics and Informatics In Drug Discovery (AMIDD)*

December 6th, 2019, 12:15-13:00

Seminarraum 5.002, Department of Mathematics and Informatics, University of Basel, Spiegelgasse 1, 4051 Basel

The mathematics behind medicine prediction

Speaker: Dr. Benjamin Ribba

Benjamin Ribba holds a Master degree and PhD in applied mathematics. He started his career as a fellow of a EU Marie Curie program dedicated to the application of mathematics to biology and medicine in Israel. He was successively assistant professor in computer science from 2008 to 2015 in France where he focused his research on the development and application of mathematical models to address questions around optimization of the efficacy and delivery of anti-cancer drugs in patients. In 2015, he joined Roche Pharma Research and Early Development. He is the author of ca. 50 publications in peer-reviewed scientific journals.